Table of contents
Varicose veins & Co. – what does ‚Co.‘ hide? Why ‚Co.‘ at all? Aren't varicose veins simply a venous or venous valve weakness, a cosmetically unpleasant appearance, also regarding pain?
What are varicose veins?
Veins transport blood back to the heart. To prevent blood from flowing back against gravity, veins have small Closures (Venous valve), which open upwards and close downwards. Thus, blood that has passed the valve cannot flow back.
With varicose veinsVaricose veins) these valves fail. The blood strains in the vein, the pressure rises, the vein wall gives way, the vein expands and arches visible under the skin, snaking and bluish-purple.
Primäre Krampfadern sind in etwa 95% auf einer Bindegewebsschwäche oder genetischer Veranlagung zurückzuführen, die sich für Nachkommen bei einem betroffenen Elternteil in 45%, bei beiden Elternteilen in 90% Wahrscheinlichkeit an Krampfadern zu erkranken auswirkt.
Causes and risk factors
The most common reason is so that a Congenital connective tissue weakness. The vein wall is naturally less elastic and stable. This is why varicose veins tend to run in families.
Furthermore, factors such as prolonged standing, sitting, being overweight, pregnancy (due to increased abdominal pressure), lack of exercise, and age (as connective tissue loses stability and flexibility over time) are all contributing factors.
The often underestimated development
Varicose veins are therefore not purely a cosmetic problem as initially stated. They develop gradually in stages. Most people only notice them late, when the process is already far advanced.
Initially, often only seemingly harmless Spider veins, fine, reddish-bluish veins directly under the skin. Initially, these are only a cosmetic concern. Over time, visible, enlarged superficial veins appear, combined with a feeling of heaviness in the legs. This is accompanied by a sensation of tightness and swelling in the evenings. The blood is now pooling so severely that fluid is leaking from the vessels into the surrounding tissue.
Without treatment, chronic changes occur, such as brownish-red discolorations of increasingly drier, and thus itchy skin, as well as hardening of the tissue, because tissue circulation is permanently impaired.
In advanced stages, Open wounds (Leg ulcer). Wounds that do not close on their own due to poor blood circulation. These are very painful and difficult to treat. The risk of Phlebitis (Thrombophlebitis), because the superficial vein becomes inflamed, hard, and painful.
The most dangerous complication is the deep vein thrombosis. This is a blood clot that forms in a deep vein of the leg. The life-threatening danger is a Pulmonary embolism, when the clot breaks loose and is carried through the bloodstream to the lungs. There, it blocks blood vessels, which can be fatal within minutes.
What many don't know
Varicose veins are therefore not a cosmetic problem, but a serious one Connective tissue warning sign. People with varicose veins often also have weaker connective tissue elsewhere, such as in heart valves, in the abdominal cavity (hemorrhoids are anatomically related venous changes), in joints, or in internal organs.
Varicose veins in the leg are often just the visible part of a systemic connective tissue problem, an expression of an internal process that began much earlier.
With internal bleeding through porous vascular walls, it is a serious medical condition. The plant compounds mentioned can supportive act and are always to be seen in the context of medical clarification.
Connective tissue weakness – genetic causes
Collagen Genes
COL3A1 Highest Danger
Chromosome 2q31 · Encodes pro-alpha1(III)-collagen
Mutations in COL3A1 cause vascular Ehlers-Danlos syndrome (vEDS). Type III collagen is a major component of the walls of medium-sized arteries, hollow organs, and the skin.
Mutation types and severity
- Glycine-sense mutations (Gly→X in (Gly-X-Y)n repeats): disrupt triple helix → dominant-negative effect → most severe phenotypes
- Splice site mutations (donor > acceptor): moderate severity
- Null/Haploinsufficiency mutations: milder phenotype, longest survival
Molecular mechanism
Mutated collagen III accumulates in the ER → ER stress → activates PLC/IP3/PKC/ERK signaling pathway → uncontrolled smooth muscle cell activation → spontaneous arterial rupture.
Clinical consequences
Spontaneous arterial dissection/rupture (esp. mesenteric arteries), intestinal and uterine rupture, internal bleeding.
Study Links
- PMC8609142 – vEDS Mechanisms
- PMC6994142 – PLC/ERK signaling pathway
- PubMed 36262204 – Artery damage
- PubMed 15127738 – vEDS Review
COL1A1 / COL1A2
Chr. 17q21.33 / Chr. 7q22.1 (Chromosome positions: COL1A1 is on chromosome 17 / COL1A2 on chromosome 7) · Coding pro-α1(I) and pro-α2(I)
Mutations in COL1A1 and COL1A2 Osteogenesis imperfecta (OI) and classic EDSEhlers-Danlos SyndromeType I collagen is the most common structural protein in the body (bones, tendons, skin, blood vessels).
Mechanism
Glycine substitutions in the triple helix → structurally unstable fibrils → reduced mechanical resistance. Null mutations → quantitative collagen deficiency (OI Type I)Osteogenesis imperfecta)).
Combination effects
Simultaneous COL1A2 + FBN2 mutations generate synergistic ECM dysfunctionExtracellular Matrix – a structure that surrounds and supports cells) with a particularly severe skeletal phenotype (Study 2022).
Study Links
- PMC9270787 – COL1A2+FBN2
- Adv. Rheumatol. 2024 – Review
COL5A1 / COL5A2
Chr. 9q34.3 / Chr. 2q32.2 · Type V Collagen
Major genes of classical EDS. Type V collagen regulates the fibril thickness of type I collagen through nucleation control.
Mechanism
Haploinsufficiency in COL5A1 → uncontrolled fibril thickness → dermal and vascular hyperextensibility, atrophic scarring.
NGS panels for classical EDS routinely analyze COL5A1, COL5A2, COL3A1, COL1A1, COL1A2, TNXB, and others.
Study Link
- PMC9164033 – NGS cEDS Panel
Fibrillin System
FBN1 / FBN2 – Microfibrils and TGF-β Regulation
FBN1 Marfan Syndrome
Chr. 15q21.1 · 66 Exons · encodes Fibrillin-1 glycoprotein
Fibrillin-1 is the main component of the 10–14 nm wide extracellular microfibril systems, which serve as a scaffold for elastic fibers and sequester TGF-β in a latent, inactive form in the ECM.
Mutation types
3,000 pathogenic variants described. Missense mutations of the EGF-like calcium-binding domains → classic Marfan syndrome. Truncating mutations → variable phenotype.
Central mechanism
Defective Fibrillin-1 → reduced sequestration of large latent TGF-β complexes (LLCs) via LTBPs → uncontrolled TGF-β release → SMAD2/3 phosphorylation + ERK1/2 activation → pathological aortic remodeling, aneurysm.
Phenotypes
Thoracic aortic aneurysm/dissection (TAAD), ectopia lentis, scoliosis, mitral valve prolapse, dural ectasia.
Study Links
- NCBI GeneReviews – FBN1/Marfan
- PMC6639799 – FBN1 Overview
- PubMed 23788295 – TGF-β in Marfan syndrome
- PubMed 20351703 – Marfan Review
FBN2
Chr. 5q23.3 · Fibrillin-2
FBN2 mutations cause Congenital Contractural Arachnodactyly (CCA), a dominant connective tissue disorder with a Marfan-like appearance.
Mechanism
Fibrillin-2 is particularly active during early embryonic development and regulates BMP signaling. Mutations in exons 24–34 are particularly common.
FBN2 and COL1A2 share the ECM organization pathway; synergistic mutations of both genes produce significantly more severe skeletal phenotypes.
Study Links
- Hum. Genome Var. 2024 – FBN2
- Genetics in Medicine - HDCT
Elastin & Cross-linking
Elastin
ELN
Chr. 7q11.23 · Tropoelastin precursor
Elastin is the structural protein of elastic fibers. Tropoelastin monomers are deposited extracellularly on fibrillin microfibrils and cross-linked by lysyl oxidases.
ELN mutations
Heterozygous deletions → Supravalvular aortic stenosis (SVAS). ELN is also part of Williams-Beuren syndrome (7q11.23 deletion). Homozygous ELN null mutations would be lethal.
ECM context
Elastin provides restoring force to arterial walls. Fragmentation of elastic lamellae leads to arterial rigidity, aneurysm formation, and venous wall weakness.
Study Link
- Front. Genet. 2022 – Heritable CTD
LOX-Gen Family
LOX / LOXL1–4
Chr. 5q23.1 (LOX) · Copper-dependent amine oxidases
Lysyl oxidases initiate covalent cross-linking of collagen and elastin: oxidation of lysine ε-amino groups → aldehydes → spontaneous pyridinoline/desmosine fibrils.
LOX Mutations
Loss-of-function variants → familial TAAD. LOX knockout mice die perinatally from aortic rupture with 60% reduction of elastin cross-links and 40% reduction of collagen cross-links.
Mechanism
Defective cross-linking → structurally unstable elastic lamellae → increased elastase susceptibility → progressive fragmentation → aortic dissection. TGF-β-responsive genes are upregulated in LOX mutants.
LOXL2/L3
In aortic dissection: LOXL2↑ → MMP2↑ → ECM degradation; LOXL3↑ → VSMC proliferation.
Study Links
- PMC4978273 – LOX Mutation TAAD
- Circulation – LOX-Knockout
- PMC8292648 – LOX in AD
- PubMed 34281165 – LOX variants
- PMC6693828 – LOX ER-Retention
TGF-β axis
TGFBR1 · TGFBR2 · SMAD2/3 · TGFB2/3 – Loeys-Dietz Syndrome
Central Signaling Pathway: TGF-β-SMAD Axis
TGF-β is sequestered in the ECM in a latent form by LTBPs (latent TGF-β-binding proteins) on fibrillin microfibrils. Defective microfibrils (FBN1 mutations) or direct receptor mutations lead to uncontrolled TGF-β activation:
Latent TGF-β (ECM) → Release → TGFBR2:TGFBR1 Heterodimer → SMAD2/3 Phosphorylation → Nuclear Complex with SMAD4 → Gene Expression (MMP↑, Collagen↓, Inflammation↑)
Parallel: Non-canonical paths across ERK1/2, p38-MAPK, PI3K/AKT enhance vascular remodeling.
TGFBR1 / TGFBR2
Chr. 9q22 / Chr. 3p24.1 · TGF-β Receptors I and II
Mutations in TGFBR1 or TGFBR2 cause Loeys-Dietz syndrome (LDS), a TAAD syndrome with bifid uvula, craniofacial features, and marked vascular fragility.
Paradox
Despite activating receptor mutations, downstream TGF-β signaling reinforced (not As expected reduces) – Mechanism: compensatory upregulation of TGFBR1/2 expression.
Study Link
- GeneReviews - LDS Gene
SMAD2 / SMAD3
Chr. 18q21 / Chr. 15q22 · Intracellular signaling mediators
Heterozygous loss-of-function mutations in SMAD3 cause aneurysma-osteoarthritis syndrome (LDS type 3): aortic aneurysms combined with early-onset osteoarthritis.
SMAD3 mutations show that canonical TGF-β signaling can paradoxically be protective of blood vessels - its loss leads to uncontrolled ECM degradation.
Study Link
- PMC6639799 – FBN1/TGF-β
ACTA2 / MYH11 / MYLK
Chr. 10q23 / 16p13 / 3q21 · VSMC contractile apparatus
These genes encode vascular smooth muscle cell (VSMC) proteins: alpha-smooth muscle actin (ACTA2), beta-myosin heavy chain (MYH11), and myosin light chain kinase (MYLK).
Mechanism
Mutations disrupt VSMC contraction and mechanosensing → secondary ECM remodeling → TAAD. ACTA2 mutations also cause cerebral and coronary artery disease.
Study Link
- PubMed 39064294 – vEDS Management
FOXC2 · VEGFC/VEGFR3 – Varicose Veins & Venous Insufficiency
FOXC2 Varicose Veins
Chr. 16q24.1 · Forkhead transcription factor
FOXC2 encodes a forkhead transcription factor essential for the development and maintenance of venous and lymphatic valves. FOXC2 regulates Delta-like 4 (Dll4), Hey2, and CXCR4 pathways in endothelial cells.
Pathomechanism
FOXC2 loss-of-function mutations → Lymphedema-Distichiasis syndrome with varicose veins. Twin study (n=2,060 pairs) showed genetic heritability of varicose veins of 86%(95%-CI: 73–99% ) and linkage to marker D16S520 near FOXC2.
Venous valve insufficiency
In all 18 examined FOXC2 mutation carriers: pathological reflux in the great saphenous vein (vs. 1/12 controls, p<0.0001). 78% also affected with the deep vein system.
Molecular
FOXC2-AS1 (lncRNA) → activates FOXC2-Notch signaling pathway → VSMC phenotype switch (contractile→synthetic), proliferation, migration → Intimal hyperplasia in varicose veins.
Study Links
- PMC1736007 – FOXC2 Twin Study
- Circulation 2007 - FOXC2 Valves
- Biol. Res. – FOXC2-AS1/Notch
- Biomarkers in Medicine – Cardiovascular Disease Review
- NCBI Bookshelf – Pathophysiology VV
MMP-2 / MMP-9 / TIMPs
Matrix Metalloproteinases · ECM Remodeling
In varicose veins, MMP-2 and MMP-9 are upregulated. MMP-2 activation leads to relaxation of the vein wall → venous dilation → insufficiency.
Mechanism
Increased hydrostatic pressure → Activation of transcription factor AP-1 → MMP induction → ECM degradation (collagen III, elastin↓) → Venous wall weakness. TIMPs control MMP activation as antagonists.
VEGF-A/VEGFR2
Hyperregulation in varicose vein walls explains venous wall permeability and inflammatory symptoms.
Study Links
Biomarkers in Medicine – MMP/TIMP
- PubMed 38980841 – Exom-Seq VV
Clinical phenotypes
Manifestations – Genes and Mechanisms Overview
| Phenotype | Primary genes | Molecular mechanism | Key signal path |
|---|---|---|---|
| Varicose veins (VV) | FOXC2, NOTCH3, MMP2, MMP9, VEGFA | Valve failure due to FOXC2 loss; MMP-mediated ECM degradation; VSMC phenotype switching | FOXC2→Notch; AP-1→MMP; VEGF-A/VEGFR2 |
| Aortic Aneurysm / TAAD | FBN1, TGFBR1/2, SMAD2/3, ACTA2, MYH11, LOX, COL3A1 | Microfibril dysfunction → TGF-β↑; LOX defect → cross-linking deficit; VSMC loss of contraction | TGF-β/SMAD; ERK1/2; PLC/IP3/PKC; LOX/ECM maturation |
| Internal bleeding / Artery rupture | COL3A1, FBN1, LOX | vEDS: Col-III dysfunction → PLC/ERK overactivation → spontaneous media rupture; LOX-KO → lack of elastin cross-linking | PLC/IP3/PKC/ERK (vEDS); LOX/Elastin-Crosslinking |
| Skin hyperextensibility / EDS | COL5A1, COL5A2, COL3A1, TNXB, ADAMTS2 | Fibril thickness dysregulation; tenascin-X deficiency → dermal collagen stability↓ | Collagen fibril nucleation; ECM maturation |
| Joint hypermobility | COL5A1, TNXB, FBN1, B3GALT6, B4GALT7 | Dermal/ligamentous ECM instability; glycosaminoglycan biosynthesis disorder (B3GALT6) | ECM Structure Protein Maturation; Proteoglycan Synthesis |
| Osteogenesis imperfecta (OI) | COL1A1, COL1A2 + 20 more (IFITM5, SERPINF1, …) | Type I collagen triple helix defects → inferior bone matrix; dominant-negative effect more severe than haploinsufficiency | Collagen I Biosynthesis; ER Stress Response |
| Loose skin | ELN, FBLN4, LTBP4, ATP6V1E1/A | Elastin cross-linking deficiency; Fibulin-4 deficiency → Tropoelastin assembly disorder; V-ATPase dysfunction | Elastin assembly; LOX maturation; Fibulin-ECM interaction |
| Marfan syndrome | FBN1 (≥90%); rarely FBN2 | Fibrillin-1 defect → TGF-β overactivation → aortic VSMC dysfunction; ectopia lentis; skeletal overgrowth | FBN1/LTBP/TGF-β/SMAD; Angiotensin-II/AT1R |
Signaling pathways
Overview of Molecular Signaling Pathways
1. TGF-β / SMAD Canonical Pathway
FBN1 Mutation → LTBP Release → TGF-β Activation → TGFBR2:TGFBR1 → SMAD2/3-P → SMAD4 Complex → Nucleus → MMP↑, Collagen III↓, CTGF↑. Disrupted in: Marfan syndrome, Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome (secondary), cutis laxa.
2. PLC/IP3/PKC/ERK (vEDS-Weg)
COL3A1 mutation → mutated collagen III in ER → ER stress (if applicable) / reduced wild-type collagen III → ECM defect → unknown mechanosensing → PLC activation → IP3 → PKC → ERK1/2 → VSMC dysfunction → spontaneous aortic rupture. Pharmacologically inhibitable by Cobimetinib (MEK/ERK inhibitor) and Ruboxistaurin (PKCβ inhibitor).
LOX/ECM cross-linking pathway
LOX (Lysyl Oxidase) → oxidizes lysine residues in collagen/elastin → aldehyde groups → spontaneous desmosine cross-links → mechanically stable ECM. LOX mutation/inhibition → uncrosslinked elastic lamellae → increased proteolysis susceptibility → aortic dilation. Associated with TGF-β (positively regulated) and MMP2/AKT pathways (via LOXL2).
FOXC2-Notch-Venous Pathway
FOXC2 (Forkhead-TF) → regulates Dll4, Hey2, CXCR4 in endothelial cells → venous valve development and maintenance. FOXC2-AS1 (lncRNA) → FOXC2↑ → Notch activation → VSMC phenotype change (SM22α↓, Osteopontin↑) → proliferation/migration → venous intimal hyperplasia, valve failure.
5. MMP/TIMP Balance
Hydrostatic pressure / mechanical stress → AP-1 activation → MMP-2/-9 transcription → collagen III/elastin cleavage → vein wall relaxation / vascular insufficiency. TIMPs (1–4) control MMP activity. Disequilibrium → chronic venous insufficiency, varicose veins, ulcerations. VEGF-A/VEGFR2: activated in parallel.
Angiotensin II / AT1R / ERK (Marfan)
Wall stress + hypertension → AT1R upregulation → Angiotensin II → TGF-β production↑ (AT1R-dependent) + ERK1/2 activation. Therapeutic approach: Losartan (AT1R blocker) reduces TGF-β and slows aortic dilation in MFS mouse models and clinical trials.
Gene reference
More relevant genes at a glance
| Gene | Chromosome | Syndrome / Role | Inheritance |
|---|---|---|---|
| TNXB | 6p21.3 | Tenascin-X Deficiency EDS | AR (complete) / AD (haploinsufficiency) |
| ADAMTS2 | 5q35.3 | Procollagen-N-Peptidase; EDS kyphoscoliotic type | AR |
| PLOD1 | 1p36.2 | Lysyl hydroxylase; Hydroxylysylpyridinoline cross-linking; kEDS | AR |
| NOTCH1/3 | 9q34.3 / 19p13 | NOTCH3: CADASIL; NOTCH1: Aortic valve disease; Venous dysfunction | AD |
| PRKG1 | 10q11.2 | cGMP-dependent protein kinase I; TAAD; VSMC relaxation defect | AD |
| BGN | Xq28 | Biglycan (Proteoglycan); X-linked TAAD; TGF-β Sequestration | X-linked |
| FLNA | Xq28 | Filamin A; periventricular nodular heterotopia; aortic pathology | X-linked dominant. |
| SLC2A10 | 20q13.1 | GLUT10; Arterial Tortuosity Syndrome; TGF-β Modulation | AR |
| LTBP4 | 19q13.2 | Latent TGF-beta-binding protein; Cutis laxa type IB | AR |
| FBLN4/5 | 11q13 / 14q32.1 | Fibulin-4/-5; Elastin fiber assembly, cutis laxa | AR |
All information is based on peer-reviewed primary literature. (As of: 2024)
Clinical decisions require genetic counseling.
Genetic findings must always be interpreted in a clinical context.
Diagnostics
Color Doppler sonography
- Identification of insufficient perforating veins
- Determination of the proximal and distal insufficiency points (crucial for surgical scope)
- Exclusion of deep vein thrombosis
Photoplethysmography (PPG)
To quantify venous pump function (which, according to guidelines, cannot solely justify surgery).
The Venous Clinical Severity Score (VCSS) and quality of life instruments such as AVVQ or CIVIQ objectify the burden of complaints for study purposes and individual treatment decisions.
Therapy (according to guideline)
Endovenous Thermal Ablation (ETA)
The current S2k Guideline (AWMF 037-018) and international guidelines recommend for symptomatic great saphenous vein insufficiency Endovenous thermal procedures before surgical procedures or foam sclerotherapy. Mechanism: Laser energy or radiofrequency (VNUS procedure) generates thermal denaturation of the vein wall from the inside → fibrosis → permanent closure.
A retrospective study published in 2025 (n=300, Alwahbi 2025) confirmed that endovenous laser ablation ambulatory under tumescent local anesthesia can be carried out safely and effectively – an important step towards reducing perioperative workload.
Radially emitting laser fibers (like with the ELVeS Radial system) show similar closure rates compared to older bare-tip fibers, with a tendency for less pain and bruising.
Surgical stripping (Crossectomy + Babcock stripping)
Contrary to popular belief, the classic stripping procedure still shows in studies low recurrence rates and is further indicated in pronounced trunk varicosis with large vein diameter or in contraindications for endovenous procedures. The disadvantages are open access and the risk of transient cutaneous nerve damage.
Sclerotherapy
Method of choice for Recurrent varicose veins and in older, multimorbid patients. Sclerotherapy causes localized vascular wall damage (chemical), leading to obliteration and fibrosis. In the case of saphenous vein varicosity, the recurrence rate is significantly higher than with thermal procedures, therefore it is only an alternative, not a primary procedure for the Great saphenous vein. For spider veins and reticular veins is it against the method of choice.
Venous glue (N-butyl-2-cyanoacrylate)
Closure of the vein using tissue adhesive. The advantage is that no tumescent anesthesia is necessary and no compression bandage is required. The disadvantage is the high cost. There is currently less long-term data available compared to established procedures.
Conservative therapy
According to the guideline, conservative therapy at every stage possible and sensible, even after invasive procedures as adjuvant therapy.
Compression therapy (medical compression stockings class I-III) reduces ambulatory venous pressure and has a proven effect on edema, skin changes, and ulcer healing.
In the long term, consistent compression therapy significantly reduces quality of life, which often justifies invasive intervention.
Plant-based active ingredients for vessel walls & connective tissue
OPC – Oligomeric Proanthocyanidins (highest evidence)
Sources: Grape seed extract, pine bark extract (Pycnogenol), red grape skin, blueberries
OPC is capable of directly strengthening the capillary walls by attaching itself to protein structures (collagen and elastin). This keeps the vascular walls strong, soft, and supple. Within 24 hours, the resistance of the vascular walls has almost doubled in studies.
Particularly relevant: OPC helps directly with hemorrhages and internal bleeding due to permeable blood vessels. This condition manifests, for example, as bloodshot capillaries in the eyes, immediate bruising from the slightest bump, burst blood vessels, or petechial hemorrhages under the skin.
OPC protects the collagen structures of the vascular walls, thereby counteracting excessive permeability of the vascular walls.
In combination with vitamin C, it is considered particularly effective: when OPC is administered together with vitamin C, small tears in blood vessel walls can be repaired.
Studies
Mechanism – Vascular Permeability: OPCs have been shown to inhibit lipid peroxidation, platelet aggregation, and capillary permeability and fragility, and to influence enzyme systems such as phospholipase A2, cyclooxygenase, and lipoxygenase.
Study Link
- 10767669
Mechanism – Collagen & Vascular Wall Structure OPCs act as natural collagen cross-linkers and prevent the proteolytic degradation of collagen types I and III by metalloproteinases, contributing to the stability of vascular walls.
Study Link
- 37097399
Experimental evidence – Capillary permeability: In an animal model (collagenase-induced vascular permeability), pretreatment with procyanidolic oligomers (PCO) was shown to significantly prevent increased capillary permeability in cerebral capillaries, aorta, and myocardial capillaries.
Internal bleeding / hemorrhages – directly relevant: OPCs complex proteins and inhibit enzymes involved in the degradation of vascular tissue. This protein-binding effect protects the structural integrity of arteries and veins.
Study Link
Alt Med Review - Full Text PDF
Study data on dosage
In clinical trials, doses between 50 and 300 mg daily have been used. For general antioxidant protection, 50 mg/day is recommended; 100 mg/day (2x 50 mg) can strengthen capillaries; symptoms of chronic venous insufficiency were alleviated starting at 150 mg/day.
Study Link
- EBSCO Research Starters
Specifically for capillary bleeding and venous insufficiency: In a clinical study with 24 patients with uncomplicated chronic venous insufficiency, 100 mg OPC/day was administered orally. Over 80 % of patients showed a positive clinical response – significant symptom improvement was already noticeable after the first 10 treatment days. No side effects were reported.
Study Link
- PubMed PMID 10356940
In a double-blind study with 50 patients with varicose veins, 150 mg/day grape seed OPC was more effective in reducing symptoms than the bioflavonoid diosmin. Another double-blind, placebo-controlled study with 71 subjects showed a significant improvement in severity, swelling, and leg discomfort with 100 mg three times daily (= 300 mg/day) – in 75 % of the OPC group within one month.
Study Link
- OPC Reference Guide – Source-Based
OPC Dosage Levels Summary:
| Goal | Dose/Day | Basis of study |
|---|---|---|
| Prevention / Antioxidant | 50–100 mg | General consensus data |
| Capillary reinforcement | 100 mg | The influence of dietary fatty acids on breast cancer. |
| Venous insufficiency, edema | 150–300 mg | Multiple RCTs |
| Acute Phase / Therapeutic | 300–500 mg | Clinical experience |
Sources / Preparations
Purchase criteria
- Actual OPC content (not just „polyphenols“ or „grape seed extract“) must be declared
- The measurement method should be the Masquelier-HPLC method or the vanillin method.
- Raw material preferably from France (highest natural OPC content)
- Do not take with protein sources (milk) - reduces absorption
Preparations
ANTHOGENOL® MASQUELIER’s® Original OPCs Capsules
The only OPC preparation that is based exactly on the Masquelier original extract tested in clinical studies.
- Contents: 100 mg Masquelier’s® Original OPCs per 2 capsules (75 % Common Wine Grape, 25 % Maritime pine)
- The taxifolin from pine bark complements the spectrum of grape seed OPC to a complete proanthocyanidin profile.
- Available in Germany, Austria, Switzerland through pharmacies and online pharmacies (e.g., Shop Apotheke, bio-apo.com)
- Price: approx. €48–55 / 90 capsules (= approx. 45 days at 2 capsules/day)
- Also as Drops available (for people with swallowing difficulties)
Medverita OPC 95% Traubenkernextrakt
- 300 mg Extract / Capsule, standardized to 95 % OPC = ~285 mg pure OPC / Capsule
- Clear declaration, no unnecessary fillers
- Well suited for therapeutic dosages (150–300 mg OPC/day)
Echt Vital OPC – French Grape Seed Extract
- ≥200 mg pure OPC / capsule, 95 % polyphenol content
- Genuine French raw material, no additives, vegan
- In Germany, we process
For the clinical target (vascular walls, capillary bleeding): ANTHOGENOL® offers the best proof through study proximity. For a purely high-dose OPC supply, Medverita 95 % is better (cheaper, higher dose per capsule).
OPC products must after Masquelier Method standardized and state the actual OPC content (not just total polyphenols). The pure OPC content in the extract should be approximately 40 %.
OPC should not without medical consultation along with blood thinners (e.g., Marcumar, ASA) are taken.
Horse chestnut (Aesculus hippocastanum)
Active ingredient: Aescin
Aescin improves blood circulation through the veins and seals damaged vessel walls, so that less fluid leaks from the veins into the tissue – this reduces the formation of edema and can cause existing edema to recede.
The active ingredients in horse chestnut strengthen blood vessel walls and can thus prevent excessive bruising. Preventive use may be particularly useful for people who are prone to excessive bruising.
Studies
Cochrane Review (highest level of evidence): 17 randomized controlled trials were included in the Cochrane review. In all trials, the extract was standardized to aescin—the main active compound in horse chestnut seed extract. The studies showed an improvement in leg pain, swelling, and itching.
Study Link
- Cochrane PMC 7144685
Mechanism of Action – Vessel Sealing: Aescin likely works by „sealing“ leaky capillaries, improving the elasticity and strength of veins, preventing the release of vascular-damaging enzymes, and blocking physiological events that lead to venous damage.
Study Link
- PMC 3833478
Molecular mechanism (in vitro): In in-vitro studies, aescin inhibited hyaluronidase activity by 93 %, which reduces the permeability and plasma loss from vascular wall endothelial cells, thereby preventing edema formation. Aescin shifts the balance between proteoglycan synthesis and degradation in favor of synthesis.
Study Link
- ScienceDirect – Brazilian Journal of Pharmacognosy
Meta-Analysis (13 RCTs, 1,051 patients): A systematic literature review identified 13 RCTs (1,051 patients) and 3 observational studies (10,725 patients). Leg volume, ankle and calf circumference, edema, pain, tightness, swelling, and itching were investigated.
Study Link
- PubMed PMID 12518108
Cochrane-validated study data on dosing
The most common clinically tested dosage of horse chestnut seed extract (HCSE) is 300 mg HCSE twice daily, standardized to 50 mg aescin per dose – corresponding to a Total daily dose of 100 mg aescin.
Study Link
- PMC Cochrane Summary 3833478
Most important reference study (Lancet 1996):
The key study by Diehm et al. (1996, Lancet) used exactly this dose (50 mg aescin twice daily = 100 mg/day) for 12 weeks in 240 CVI patients and showed results comparable to compression therapy.
Dosage chart Aescin:
| Application | HCSE/Day Dose | Aescin/Tag Dosage | Duration |
|---|---|---|---|
| Therapeutic (CVI, Edema) | 600 mg (2x300 mg) | 100 mg | 8–12 weeks |
| Maintenance dose | 300–450 mg | 50-75 mg | Long term |
| Postoperative (swelling) | 20–40 mg Aescin | direct | short-term |
Use only esculin-free, standardized extracts (16–20 % aescin). Do not use in patients with kidney or liver disease. Note interactions with anticoagulants.
Sources / Preparations
Horse chestnut extract is in Germany as an approved medicinal product available – this is an important quality advantage over dietary supplements, as efficacy and standardization are regulated.
Purchase criteria
- At least 100 mg Aescin/Tag (Cochrane-validated minimum dose)
- Extraction with alcohol (not just water – aescin is barely soluble in water!)
- Standardization to 16–20 % Aescin
- Prefer slow-release (more even release)
- Esculin-free – the contained toxin must have been removed
Preparations (all authorized medicines)
Venostasin® retard 50 mg – Klinge Pharma
- The reference drug used in the majority of clinical trials
- 50 mg Aescin/Capsule (sustained-release), 2 capsules/day = 100 mg Aescin/Tag
- Prescription drug, available only in pharmacies
- Available from Shop Apotheke, DocMorris, and all local pharmacies, among others
- Price: approx. €15–20 / 50 capsules
Aesculaforce® forte Venen – A.Vogel (also Switzerland)
- 50 mg Aescin / Film-coated tablet from fresh horse chestnut seeds (mother tincture)
- 2 tablets/day = 100 mg aescin/day
- Approved medicinal product according to phytotherapy standard
Aescuven® forte – Cesra
- Standardized dry extract, standardized to aescin
- Approved medicinal product, subject to pharmacist sale
Venostasin® retard – best-documented preparation, used directly in clinical studies, regulatorily approved, cost-effective.
Red vine leaf (Vitis vinifera)
Active ingredients Flavonoids, Quercetin, OPC
Red vine leaf protects capillaries and has antioxidant effects. It is one of the classic phytotherapeutic agents for venous insufficiency and connective tissue weakness.
Pine bark extract (Pycnogenol®)
Active ingredients Proanthocyanidins, Bioflavonoids
Pine bark extract strengthens collagen structures and, like grape seed extract, contains highly concentrated OPC. It is considered particularly bioavailable and is a good alternative for people with grape intolerance.
Reishi Mushroom (Ganoderma lucidum)
Active ingredients Triterpene, Beta-Glucan
Reishi triterpenes lower blood pressure and strengthen the cardiovascular system. As radical scavengers, age-related damage to the heart, liver, and kidneys can be reduced, as can arteriosclerotic vascular constrictions.
Reishi indirectly protects blood vessels due to its strong antioxidant and anti-inflammatory properties – it protects the vascular endothelium from oxidative stress.
Studies
Cardiovascular Effects – Cochrane/Review: Several in vitro studies and animal models have shown antioxidant, antihypertensive, lipid-lowering, and anti-inflammatory properties of G. lucidum. However, evidence from clinical studies is inconsistent, partly due to different formulations.
Study Link
- PMID 34465259
Active Ingredients and Mechanisms The pharmacologically most important components of G. lucidum are triterpenes and polysaccharides. Triterpenes have hepatoprotective, antihypertensive, hypocholesterolemic, and antihistaminergic effects; polysaccharides (especially β-D-glucans) have antioxidant effects and protect cells from mutagenic damage.
Study Link
- ScienceDirect
Study data on dosage
In the largest placebo-controlled RCT to date (84 participants, 16 weeks), the researchers used 3 g Ganoderma lucidum daily (8 capsules, divided into 4 in the morning and 4 in the evening, with meals). This dose was based on literature recommendations available at the time.
Study Link
- PMC 4980683 / Scientific Reports RCT
In a safety study with 16 healthy volunteers, 2 g Reishi extract twice daily (= 4 g/day) administered for over 10 days. No side effects were observed compared to the placebo group.
Study Link
- 17597499
A GRADE-rated systematic review and meta-analysis (2025) examined clinical trials with Ganoderma doses of 200 to 11,200 mg/day over 1-24 weeks. Reishi showed significant reductions in BMI, creatinine, and heart rate. No significant effect was found on blood pressure, blood lipids, or fasting glucose.
Study Link
- PMC 12160064
Dosage Chart Reishi:
| Goal | Dose/Day | dosage form | Study base |
|---|---|---|---|
| Immunomodulation / General | 1,000–1,500 mg Extract | Capsules | PMID 17597499 |
| Cardiovascular risk factors | 3,000 mg | Capsules (4x2) | PMC 4980683 |
| Therapeutic (Cancer, Fatigue) | 3,000–5,400 mg | Spore powder | PMID 39241163 |
Sources / Preparations
Purchase criteria
- Nur Fruiting body extract (no mycelium or mycelium on grain – very low active ingredient content!)
- Standardization on Polysaccharide/Beta-Glucan ≥ 20–30 % and/or Triterpenes
- For cardiovascular / antioxidant effect: Dual extract (Water + Alcohol) are preferred, as triterpenes are only soluble in alcohol
- Organic cultivation + Heavy metal testing (Mushrooms accumulate heavy metals!)
- PZN number = registered in Germany = minimum standard met
Preparations
Bio Reishi Extract+Powder – Pestalozzi Pharmacy (Hawlik Vital Mushrooms)
- Combination of fruiting body extract + fruiting body powder
- Certified organic, rich in polysaccharides and beta-glucans
- Combined with organic acerola (natural vitamin C)
- Available at Pestalozzi Pharmacy and Bahnhof Pharmacy Kempten
Vital Mushroom Chiemsee Organic Reishi Extract
- 30 % Polysaccharide (Beta-Glucan) guaranteed, fruiting body only
- Multiple pollutant tests (heavy metals, pesticides, mycotoxins)
- Shellbroken procedure for maximum bioavailability
Raab Vitalfood Organic Reishi Capsules
- Aqueous extract, controlled organic cultivation
- Combined with Acerola (Vitamin C) for a synergistic effect
- Standardized polysaccharide concentration
- Available through many pharmacies and natural food stores
Restriction For the vascular-stabilizing effect (triterpenes), a Dual extract required. Pure water extracts contain few triterpenes. Hawlik offers dual extracts; please explicitly check the product data sheet for triterpenes when purchasing.
Note: The 2015 Cochrane review (PMID 25686270) found that Reishi in cardiovascular risk factors no proven clinical efficacy shows. Reishi remains the active ingredient regarding vascular wall stabilization lowest clinical evidence of the four mentioned.
The extract type is crucial: for triterpenes (cardiovascularly relevant), a Dual extract (Water + Alcohol) present.
Maitake mushroom (Grifola frondosa)
Active ingredients Polysaccharide (Beta-Glucane)
Maitake mushroom supports healthy blood vessel function. Its potent polysaccharides strengthen the immune system and have antioxidant effects. VitaminFit
Silica / Silicon (from horsetail, bamboo extract)
Silica supports the formation of collagen and elastic fibers VitaMoment – both are structural proteins that build blood vessel walls and ensure their stability.
Sweet clover (Melilotus officinalis)
Active ingredients Coumarin, Flavonoids
Sweet clover promotes lymph flow and has decongestant effects. Purazell – thereby supporting microcirculation and relieving pressure on blood vessel walls.
Ivy (Hedera helix)
Herbal applications with ivy leaves can strengthen connective tissue. Dr. Gumpert – traditionally used as a compress or infusion.
Essential Micronutrients as Plant-Based Companions
| Material | Effect |
|---|---|
| vitamin C | Essential for collagen synthesis; synergistic with OPC |
| Flavonoids | Strengthens vein walls and valves Smarticular |
| Zinc | Collagen Formation & Wound Healing |
| manganese | Key role in the formation of chondroitin sulfate, a central building block of connective tissue Purazell |
Vitamin C / Ascorbic Acid (best understood at a molecular level)
Basic Mechanism – Collagen & Vascular Wall: Vitamin C is a cofactor for prolyl and lysyl hydroxylases, which stabilize collagen types I and VI. Collagen type IV forms the main building block of vessel walls and basement membranes. Vitamin C deficiency leads to the inhibition of collagen transcription in blood vessels through epigenetic DNA hypermethylation.
Study Link
- NCBI Bookshelf – StatPearls
Clinical Relevance – Capillary Bleeding: Acute vitamin C deficiency is characterized by microvascular complications like widespread capillary hemorrhages. Ascorbate is required for the synthesis of collagen, the protein most critical for maintaining vascular integrity.
Study Link
- PubMed PMID 8692035
Clinical Picture Scurvy: Hemorrhages are a typical characteristic of vitamin C deficiency: perifollicular hemorrhages, petechiae, ecchymoses, and coagulopathies can be attributed to the reduced integrity of connective tissue due to impaired collagen synthesis.
Study Link
- PMC 10296835
Basic supply (RDA) vs. therapeutic dose
The recommended daily allowance (RDA) for adults is 75 mg/day for women and 90 mg/day for men. Smokers require an additional 35 mg/day due to increased oxidative stress. For the prophylaxis of complex regional pain syndrome after wrist fracture, high-quality studies have 500 mg daily for 50 days used.
Study Link
- Journal of Orthopaedics – PDF
Vascular / endothelial effect
For the optimal synthesis of collagen type IV (the main building block of the vascular basement membrane) by endothelial cells, intracellular ascorbate concentrations in the low millimolar range are required. In a clinical study in heart failure patients, an intravenous bolus of 2.5 g ascorbate, followed by 2 g/day for 3 days, lowered apoptotic endothelial microparticles to 32 % of baseline.
Study Link
- PMC 3869438 – Role of Vitamin C in the Vascular Endothelium
Study data on dosage
| Purpose | Dose/Day | Basis of study |
|---|---|---|
| RDA (Basic Supply) | 75–90 mg | Official Nutrition Societies |
| Collagen synthesis optimum oral | 200–500 mg | PMC 6204628 |
| Vascular endothelium / vascular effect | 500–1,000 mg | PMC 3869438 |
| Therapeutic for scurvy symptoms | 500–1,000 mg | Mitochondrial DNA copy number as a predictive biomarker for severe COVID-19 in patients with rheumatoid arthritis. |
| Synergy with OPC | Greater than or equal to 500 mg | Clinical Experience (Morishige) |
Vitamin C is the strongest, cheapest, and safest Agents for vascular walls. When taken orally, the absorption rate decreases significantly above 200 mg.
This is why liposomal vitamin C is more efficient when taken throughout the day (e.g., 2x 250 mg).
The strongest herbal remedies specifically for porous blood vessels and hemorrhages according to the current state of research, is it Grape Seed Extract / Pine Bark Extract in Combination with natural vitamin C.
German
Afrikaans
Chinese
Czech
Danish
Dutch
English
Finnish
French
Greek
Hungarian
Italian
Japanese
Latvian
Lithuanian
Norwegian
Portuguese
Slovak
Slovenian
Spanish
Swedish
Russian
Turkish